Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Journal of controlled release : official journal of the Controlled Release Society
Using three established ionizable lipids, researchers measured RNA, lipid components, lymphatic transport, plasma exposure, and tissue reporter expression in rats. After subcutaneous injection, lymph concentrations exceeded plasma concentrations, but lipid and RNA trafficking did not fully match. The study demonstrates why tracking a lipid label alone may not accurately represent intact RNA delivery or productive expression in tissues.
A Perspective proposes designing mRNA vaccine materials around changing immune conditions before and after cancer surgery. The framework considers a broadly applicable preoperative prime followed by a personalized postoperative boost, with carriers controlling expression and immune activation. It is a conceptual design roadmap, not evidence from a new clinical trial.
Researchers developed BET-targeting PROTACs that recruit the tissue-restricted scaffolding protein MAGEA11 rather than relying on widely expressed ligases. Lead compound 105B degraded BET proteins in two cancer cell lines but not in HEK293T cells. Mechanistic experiments implicated MAGEA11 and HUWE1. The authors emphasized that further optimization is needed to produce selective cytotoxicity.
MEPSGEN has launched NanoCalibur Mini for automated formulation of lipid and polymeric nanoparticles at volumes of 0.1 to 3 milliliters. The system targets early screening when payloads and excipients are scarce. The company says its platforms retain identical microfluidic mixing geometry across scales and increase throughput through parallelization, an approach intended to reduce process redevelopment during technology transfer.
WuXi AppTec reported nine-month 2026 revenue of RMB 45.54 billion, up 38.6% year over year. Revenue from continuing operations rose 46.3%, and continuing-operations backlog reached RMB 76.74 billion, up 36.4%. The company also raised full-year guidance. Total-revenue and continuing-operations growth rates use different reporting scopes and should not be treated as interchangeable.
Moderna reported detailed results from the randomized, double-blind Phase 3 INTerpath-001 trial in completely resected stage IIB–IV melanoma. Adding intismeran autogene to pembrolizumab improved recurrence-free survival in the prespecified intention-to-treat analysis: hazard ratio 0.58 (95% CI 0.45–0.75), with 24.6 months median follow-up. Grade 3–5 treatment-related adverse events occurred in 14.2% versus 13.4%. The treatment remains investigational.
Researchers combined pyridoxine hydrochloride with mesalamine or acetazolamide and p-aminobenzoic acid to prepare ternary eutectic solids. The systems altered pH-dependent solubility and membrane permeability. Characterization distinguished a physical mixture from a cocrystal-containing eutectic, emphasizing that multicomponent formulations can have different phase identities. The reported laboratory results do not establish human bioavailability improvements.
A study of ivacaftor examined how solvent identity, liquid-additive volume, milling time, and starting solid form affect mechanochemical solvate formation. Crystalline Form C and amorphous material followed different transformation patterns. Structural and surface analyses suggest that mechanically exposed polar groups contribute to solvent incorporation, rather than solvent class or apparent dissolution capacity alone explaining the outcome.
Molecular therapy : the journal of the American Society of Gene Therapy
A ligand-free nanoparticle formulation preferentially delivered mRNA to human hematopoietic stem and progenitor cells in humanized mice without conditioning. It reduced hepatic delivery relative to an SM-102 comparator and enabled functional Cas9-mediated editing of human CD34-positive cells. Single-cell analyses supported tolerability under the conditions examined. Durable stem-cell function and clinical delivery still require further investigation.
Researchers developed a calix[4]arene-based supramolecular gel whose assembly is triggered by dihydrogen phosphate. A salt cocrystal containing furosemide and its tetrabutylammonium salt grew within the gel at a lower furosemide concentration than required in the corresponding solution. The work demonstrates a crystallization environment, rather than a clinically validated pharmaceutical formulation or a ready-to-use manufacturing process.
A Kidney Week report described pooled CORALreef trial findings for oral PCSK9 inhibitor enlicitide across kidney function groups. Participants with estimated glomerular filtration rates below 60 had a 65.9% placebo-adjusted LDL cholesterol reduction at Week 24. This subgroup analysis addresses lipid lowering; it does not establish fewer cardiovascular events, which require dedicated outcomes evidence.
Asymchem reported consolidated revenue of RMB5.395 billion, up 16.52%, and attributable net income of RMB852.2 million for the nine months ended September 30, 2026. Attributable net income grew 6.49%, trailing the increase in revenue over the same nine-month period. The quarterly filing is unaudited and covers the year-to-date period.
